$LSTA News

Lisata Therapeutics Appoints Jeff Farrow to Board of Directors

Lisata Therapeutics wins new US patent for pancreatic cancer drug

Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors

Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of Acromegaly

Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions

Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?

Lisata deal propels Marea’s drug pipeline to Wall Street

Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement

Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines For Cardioendocrine Diseases

Lisata Therapeutics moves forward with legal action following Kuva merger termination

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees

Lisata Therapeutics Terminates Merger Agreement With Kuva Labs; Termination Due To Kuva Labs' Failure To Obtain Financing, Accept Tendered Shares; Board To Carry Out Strategic Options Including Asset Sale

Lisata Therapeutics Stock Falls After Hours: Here's Why

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.